Inosine - instructions for use, dose, side effects, contraindications

The predecessor of adenosine triphosphate, stimulates metabolic processes. Has antiarrhythmic and antihypoxic effect. Improves coronary and renal circulation.

Activates metabolism in conditions of hypoxia and lack adenosine triphosphate. It penetrates into cells, strengthens the processes of metabolism in the myocardium: it increases the strength of the heart rate and provides a more complete relaxation of the cardiac muscle in the diastole, as a result of which the shock volume increases.

Reduces platelet aggregation, enhances the regeneration of tissues, mostly myocardium and mucous membrane of the gastrointestinal tract.

Pharmacokinetics:

After oral administration, it is completely absorbed in the gastrointestinal tract.

Metabolism in the liver to glucuronic acid, followed by its oxidation.

Elimination by the kidneys.

Indications:

It is used as part of complex therapy of myocardial infarction, ischemic heart disease, myocardial dystrophy. Used for fatty liver, hepatitis, cirrhosis. It is used as a means of pharmacological protection in operations on an isolated kidney.

ICD-10

I.B15-B19.B18.8 Other chronic viral hepatitis

I.B15-B19.B18.2 Chronic viral hepatitis C

I.B15-B19.B18.1 Chronic viral hepatitis B without delta-agent

I.B15-B19.B18.0 Chronic viral hepatitis B with delta-agent

IX.I30-I52.I40 Acute myocarditis

IX.I30-I52.I42 Cardiomyopathy

XI.K70-K77.K70 Alcoholic liver disease

XI.K70-K77.K71 Toxic liver disease

XI.K70-K77.K73.1 Chronic lobular hepatitis, not elsewhere classified

XI.K70-K77.K74 Fibrosis and cirrhosis of the liver

XIX.T36-T50.T46.0 Poisoning with cardiac glycosides and preparations of similar action

XXI.Z20-Z29.Z29.8 Other specified preventive measures

Contraindications:

Hyperuricemia, gout, individual intolerance, children under 18 years of age.

Carefully:

Severe renal failure, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - category is not defined. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Inside: for 600-800 mg with a gradual increase in the dose to 2.4 g per day in 3-4 doses.

Intravenously drip or spray: 200 mg once a day, with a gradual increase in the dose to 400 mg.

The highest daily dose: 2.4 g.

The highest single dose: 400 mg.

Side effects:

Allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

Enhances the inotropic effect of lantozide.

Immunoglobulin antimonotsitarny, ciclosporin, azathioprine reduce the effectiveness of inosine.

The action of inosine enhances ethylthiobenzimidazole.

Special instructions:

Control of uric acid in serum and urine.

Instructions

Inosine (Inosinum)